Castro-Martínez MG, Liceaga-Craviotto G, Alexanderson-Rosas G, Bolado-García V, d’Hyver-Wiechers C, Durán-Salgado M, Fuentes-Venegas S, Galindo-Delfín G, García-Méndez J, Godínez-Corona E, Gómez-Romero P, Gutiérrez-Reza T, Herrera-Madrigal C, Licea-Granados R, Luckie LA, Márquez-Marín M, Pliego-Reyes C, Ramos-Rodríguez R, Rubio-Guerra A, Salinas-Orozco S, Servín-Caamaño A, Vargas-Ayala G, Morales-Andrade E

Language: Spanish
References: 128
Page: 58-88
PDF size: 927.24 Kb.

ABSTRACT

The prevalence of obesity is increasing in all age groups, including the group of people over 65 years. However, appropriate clinical approach to obesity in the elderly is controversial due to the reduction in relative health risk associated with increased body mass index, the variable efficacy of drug treatment and the effects of weight loss on muscle mass and bone tissue. The purpose of this consensus, in which 20 specialists participated within the field of Geriatrics, Internal Medicine, Endocrinology, Cardiology, Psychiatry and Nutrition, was to review the clinical aspects of obesity in the elderly to provide health professionals control weight guidelines appropriate for this population. Each participant established the evidence and recommendations on the various issues addressed by greater clinical experience, being enriched by the opinions of other experts. At the end, all the evidence without a CPG reference was rated according the National Institute for Health and Clinical Excellence (NICE), and the decisions taken were unified in the document presented here. The consequences of obesity on the health of the elderly are related to the decrease in peripheral lean mass, increased visceral fat and fat deposition in muscle, liver and pancreas. Obesity is associated with morbidities such as diabetes, hypertension, dyslipidemia, metabolic syndrome, cancer, arthritis, asthma and poor physical health, among others. The relative risk of mortality and decrease in survival are altered after 60 years and the absolute risk of mortality increases with body mass index after 65 years.

REFERENCES

1. United Nations. Department of Economic and Social Affairs, Population Division. World population ageing 1950-2050. New York: UN, 2002.

2. World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, 2000.

3. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-2497.

4. Norma Oficial Mexicana NOM-037-SSA2-2012 para la prevención, tratamiento y control de las dislipidemias. Disponible en: http://www.dof.gob.mx/nota_detalle.php ?codigo=5259329&fecha=13/07/2012 México, DF: Diario Oficial de la Federación, 13 de julio de 2012.

5. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública 2012.

6. Shamah-Levy T, Cuevas-Nasu L, Mundo-Rosas V, et al. Estado de salud y nutrición de los adultos mayores en México: resultados de una encuesta probabilística nacional. Salud Pub Mex 2008;50:383-389.

7. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A, et al. Síndrome metabólico en adultos mexicanos. Resultados de la Encuesta Nacional de Salud y Nutrición 2006. Salud Pub Mex 2010;52:11-18.

8. Rosengren A, Skoog I, Gustafson D, et al. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med 2005;165:321-326.

9. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.

10. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome–a new worldwide definition. Lancet 2005;366:1059-1062.

11. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.

12. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 1998;279:585-592.

13. Burke GL, Arnold AM, Bild DE, et al. Factors associated with healthy aging: the cardiovascular health study. J Am Geriatr Soc 2001;49:254-262.

14. Mozaffarian D, Kamineni A, Prineas RJ, et al. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2008;168:969-978.

15. American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care 2014;37:14-80.

16. Han TS, Tajar A, Lean ME. Obesity and weight management in the elderly. Br Med Bull 2011;97:169-196.

17. Chahal HS, Drake WM. The endocrine system and ageing. J Pathol 2007; 211:173-180.

18. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:1016-1025.

19. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993;14:20-39.

20. Greenspan SL, Klibanski A, Rowe JW, Elahi D. Age-related alterations in pulsatile secretion of TSH: role of dopaminergic regulation. Am J Physiol 1991;260:486-491.

21. Mariotti S, Franceschi C, Cossarizza A, Pinchera A. The aging thyroid. Endocr Rev 1995;16:686-715.

22. Laughlin GA, Barrett-Connor E. Sexual dimorphism in the influence of advance aging on adrenal hormonal levels: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000;85:3561-3568.

23. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279-4284.

24. Banks WA, Willoughby LM, Thomas DR, Morley JE. Insulin resistance syndrome in the elderly:assessment of functional, biochemical, metabolic, and inflammatory status. Diabetes Care 2007;30:2369-2373.

25. Osher E, Stern N. Obesity in elderly subjects in sheep’s clothing perhaps, but still a wolf! Diabetes Care 2009;32:398-402.

26. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995;141:1117-1127.

27. Villareal DT, Apovian CM, Kushner RF, Klein S, American Society for Nutrition; NAASO. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO. The Obesity Society. Am J Clin Nutr 2005;82:923-934.

28. Evaluación y control nutricional del adulto mayor en primer nivel de atención. México: Secretaría de Salud, 2008.

29. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1996;54:559-565.

30. Reyes-Morales H, Doubova SV, García-González JJ, et al. Guía para la evaluación gerontológica integral. Rev Med Inst Mex Seguro Soc 2009;47:291-306.

31. Bray G, Bouchard C, James WPT. Definitions and proposed current classifications of obesity. Handbook of obesity. New York: Marcel Dekker, 1998;31-40.

32. Salas-Salvadó J, Rubio MA, Barbany M, Moreno B, Grupo Colaborativo de la SEEDO. Consenso SEEDO 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin (Barc) 2007;128:184-196.

33. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tis- sue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-468.

34. American Association of Clinical Endocrinologist/American College of Endocrinology (AACE/ACE), Obesity Task Force. AACE/ACE Position statement on the prevention, diagnosis, and treatment of obesity. Endocr Pract 1998;4:297-330.

35. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. Obes Res 1998;6:51-209.

36. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;119:655-660.

37. Kushner RF, Weinsier RL. Evaluation of the obese patient. Practical considerations. Med Clin North Am 2000;84:387- 399.

38. American Association of Clinical Endocrinologist/American College of Endocrinology (AACE/ACE) Obesity Task Force. AACE/ACE Position statement on the prevention, diagnosis, and treatment of obesity. Endocr Pract 1998;4:297-330.

39. Casanueva E, Kaufer-Horwitz M, Pérez-Lizaur AB, Arroyo P. Nutriología médica. 3ª ed. México: Editorial Médica Panamericana, 2008.

40. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the obesity society. Circulation 2014;129:102-138.

41. Sociedad Española de Nutrición Comunitaria. Guías alimentarias para la población española. Madrid: SENC, 2001.

42. de Lira-García C, Souto-Gallardo M, Bacardí-Gascón M, Jiménez-Cruz A. Revisión de la efectividad de los ingredientes de productos alternativos para la pérdida de peso. Rev Salud Pública 2008;10:818-830.

43. Revista Española de Obesidad. Recomendaciones nutricionales basadas en la evidencia para la prevención y el tratamiento del sobrepeso y la obesidad en adultos (Consenso FESNAD-SEEDO). Madrid: 2011;1.

44. Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013;347:5577.

45. Saz-Peiró P, Gálvez-Gálvez JJ, Ortiz-Lucas M, Saz-Tejero S. Ejercicio físico. Medicina Naturista 2011;5:18-23.

46. Mathus-Vliegen EMH, Basdevant A, Finer N, et al. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. Obes Facts 2012;5:460-483.

47. Dvorak R, Starling RD, Calles-Escandon J, Sims EA, et al. Drug therapy for obesity in the elderly. Drugs Aging 1997;11:338-351.

48. Bertisch SM, Wee CC, McCarthy EP. Use of complementary and alternative therapies by overweight and obese adults. Obesity 2008;16:1610-1615.

49. Tratamiento quirúrgico del paciente adulto con obesidad mórbida. Guía de práctica clínica. México: Secretaría de Salud, 2009.

50. Robert M, Pasquer A, Espalieu P, et al. Gastric bypass for obesity in the elderly: is it as appropriate as for young and middle-aged populations? Obes Surg 2014;24:1662-1669.

51. Talen MR, Mann MM. Obesity and mental health. Primary Care 2009;36:287-305.

52. Ho RC, Niti M, Kua EH, Ng TP. Body mass index, waist circumference, waist-hip ratio and depressive symptoms in Chinese elderly: a population-based study. Int J Geriatr Psychiatry 2008;23:401-408.

53. Organización Panamericana de la Salud. Depresión y demencia son los trastornos mentales que más afectan a los mayores de 60 años en el mundo (10 de octubre de 2013). Recuperado el 04/07/2014 del sitio web: http://www. paho.org/arg/index.php?option=com_content&view=art icle&id=1248:depresion-y-demencia-son-los-trastornosmentales- que-mas-afectan-a-los-mayores-de-60-anos-enel- mundo&Itemid=269

54. Belló M, Puentes-Rosas E, Medina-Mora ME, Lozano R. Prevalencia y diagnóstico de depresión en población adulta en México. Salud Publica Mex 2005;47:4-11.

55. Giuli C, Papa R, Bevilacqua R, et al. Correlates of perceived health related quality of life in obese, overweight older adults: an observational study. BCM Public Health 2014;14:35-42.

56. Wild B, Herzog W, Lechner S, et al. Gender specific temporal and cross-sectional association between BMI/class and symptoms of depressions in the elderly. J Psychosomatic Research 2012;72:376-382.

57. Fitch A, Everling L, Fox C, Goldberg J, et al. Institute for Clinical Systems Improvement. Prevention and management of obesity for adults. Updated May 2013.

58. Vieweg WV, Levy JR, Fredrickson SK, et al. Psychotropic drugs considerations in depressed patients with metabolic disturbances. Am J Med 2008;121:647-655.

59. García-Ulen C, Huizinga MM, Bench B, Elasy TA. Weight regain prevention. Clinical Diabetes 2008;26:100-113.

60. Lowe MR, Miller-Kovach K, Phelan S. Weight-loss maintenance in overweight individuals one to five years following successful completion of a commercial weight loss program. Int J Obes Relat Metab Disord 2001;25:325-331.

61. Malnick SD, Knobler H. The medical complication of obesity. QJM 2006;99:565-579.

62. Kirkman MS, Briscoe BJ, Clark N, Florez H, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc 2012;60:2342-2356.

63. Navarrete-Reyes AP, Avila-Funes JA. Diabetes mellitus y el síndrome de fragilidad en el anciano. Rev Invest Clin 2010;62:327-332.

64. Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8:29.

65. Knowler WC, Barrett-Connor E, Fowler SE, Diabetes Prevention Program Research Group, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

66. Crandall J, Schade D, Ma Y, Diabetes Prevention Program Research Group, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med 2006;61:1075-1081.

67. Knowler WC, Fowler SE, Hamman RF , Diabetes Prevention Program Research Group et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-1686.

68. García-Lara JM, Ávila-Funes JA, Aguilar-Navarro S. Tratamiento farmacológico de la diabetes en el anciano. Rev Inv Clin 2010;62:357-365.

69. Rubio AF. Hipertensión arterial en el paciente obeso. En Temas Selectos en Medicina interna 2008. México: Alfil,2008;129-138.

70. Rubio AF. Evaluación del paciente hipertenso. En Hipertensión arterial. México: El Manual Moderno, 2005:41-48.

71. Rubio AF. Hipertensión arterial en el paciente con enfermedad arterial periférica. Rev Invest Clin 2013;65:263- 268.

72. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-1357.

73. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-520.

74. Harris TB, Ballard-Barbasch R, Madans J, et al. Overweight, weight loss, and risk of coronary heart disease in older women: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1993;137:1318-1327.

75. Janssen I. Morbidity and mortality risk associated with an overweight BMI in older men and women. Obesity (Silver Spring) 2007;15:1827-1840.

76. Parati G. Management OSA and HAS Joint Recommendation by ESH/ERS. J Hypertension 2012;30:633-646.

77. Qasseman A, et al. Guidelines treatment SAOS/obesity. Ann Intern Med 2013;159:471-483.

78. Carrillo-Alduenda JL, Arrendondo del Bosque FM, Reyes- Zúñiga M, et al. Síndrome de apnea obstructiva del sueño en la población adulta. Neumol Cir Torax 2010;69:103-115.

79. Nerbass FB, Pedrosa RP, Danzi-Soares NJ. Obstructive sleep apnea and hypertrophic cardiomyopathy: A common and potential harmful combination. Sleep Med Rev 2013;17:201-206.

80. Yaggi HK, Strohl KP. Adult obstructive sleep apnea/hypopnea syndrome: definitions, risk factors and pathogenesis. Clin Chest Med 2010;31:179-186.

81. Kawaguchi Y, Fukumoto S, Inaba M, et al. Different impacts of neck circumference and visceral obesity on the severity of obstructive sleep apnea syndrome. Obesity 2011;19:276-282.

82. McCall C, McCall VW. Objective vs subjective measurements of sleep in depressed insomniacs: first night effect or reverse first night effect? J Clin Sleep Med 2012;8:59-65.

83. Egocheaga MI, Gamarra J, Hernández J. Hipertensión y apnea del sueño. Medicina general 2002;42:204-206.

84. Culebras A. Síndrome de apnea obstructiva del sueño: soluciones a corto plazo y riesgo cerebro vascular a largo plazo. Rev Neurol 2006;42:34-41.

85. Friedman O, Logan AG. The price of obstructive sleep apnea-hypopnea: hypertension and other ill effects. Am J Hypertens 2009;22:473-483.

86. Drager LF, Pedrosa RP, et al. The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea. Hypertension 2011;57:549-555.

87. Ramar K, Caples SM. Cardiovascular consequences of obese and nonobese obstructive sleep apnea. Med Clin North Am 2010;94:465-478.

88. Shanmugasundaram M, Rough SJ, Alpert JS. Dyslipidemia in the elderly: should it be treated? Clin Cardiol 2010;33:4-9.

89. Grundy SM, Cleeman JI, et al. Implication of recent clinical trails for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227- 239.

90. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-2333.

91. Gravina CF, Bertolami M, Rodrigues GH. Dyslipidemia: evidence of efficacy of the pharmacological and nonpharmacological treatment in the elderly. J Geriatr Cardiol 2012;9:83-90.

92. Miettinen T, Pyörälä K, Olsson A, et al. Cholesterollowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-4218.

93. Jellinger PS, Dickey RA, Ganda OP. The American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of dislypidemia and prevention of atherogenesis. Endocr Pract 2000;6:162-213.

94. Filippatos TD. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovasc Drugs Ther 2012;26:245-255.

95. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-122.

96. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.

97. World Cancer Research Fund/American Institute for Cancer Research. 2007. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR, 2007.

98. Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms and recommendations. Ann N Y Acad Sci 2012;1271:37-43.

99. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and mechanisms. Nat Rev Cancer 2004;4:579-591.

100. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-1226.

101. Fürstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002;3:298-302.

102. Reeves GK, Pirie K, Beral V, Million Women Study Collaboration, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134.

103. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.

104. Wearing SC, Hennig EM, Byrne NM, et al. The biomechanics of restricted movement in adults obesity. Obes Rev 2006;7:13-24.

105. Runhaar J, Koes BW, Clockaerts S, Bierma-Zeinstra SM. A systematic review on changed biomechanics of lower extremities in obese individuals: a possible role in development of osteoarthritis. Obes Rev 2011;12:1071-1082.

106. Wearing SC, Hennig EM, Byrne NM, et al. Musculoskeletal disorders associated with obesity: a biomechanical perspective. Obes Rev 2006;7:239-250.

107. Guía de práctica clínica para el diagnóstico y tratamiento de la osteoartrosis de rodilla. México: Secretaría de Salud, 2009.

108. Hochberg MC, Altman RD, April KT, Benkhalti M, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:465-474.

109. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-1155.

110. Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006;1:4257.

111. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010;341:4675.

112. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005;CD002946.

113. Wu D, Huang Y, Gu Y, Fan W. Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebocontrolled trials. Int J Clin Pract 2013;67:585-594.

114. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007;146:580-590.

115. Vismara L, Menegoni F, Zaina F, et al. Effect of obesity and low back pain on spinal mobility: a cross sectional study in women. J Neuroeng Rehabil 2010;7:1-8.

116. Guo JM, Zhang GQ, Alimujiang. Effect on BMI and WHR on lumbar lordosis and sacrum slant angle in the middle and elderly women. China Journal of Orthopaedics and Traumatology 2008;21:30-31.

117. Miyazaki J, Murata S, Horie J, et al. Lumbar lordosis angle (LLA) and leg strength predicts walking ability in elderly males. Arch Gerontol Geriatr 2013;56:141-147.

118. Visser WE, Visser TJ, Peeters RP. Thyroid disorders in older adults. Endocrinol Metab Clin North Am 2013;42:287-303.

119. Clinical Practice Guidelines for Hypothyroidism in Adults. Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012;22:1200-1235.

120. Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J 2013;2:215-228.

121. Fatourechi MM, Fatourechi V. An update on subclinical hypothyroidism and subclinical hyperthyroidism. Expert Rev Endocrinol Metab 2014;9:137-151.

122. Devdhar M, Ousman YH, Burman KD. Hypothyroidism. Endocrinol Metab Clin North Am 2007;36:595-615.

123. Ismail IS, Bebakar WM, Noor MI, et al. Clinical practice guidelines on management of obesity. Ministry of Health Malaysia (MHM), Academy of Medicine of Malaysia (AMM), Malaysian Association for the Study of Obesity (MASO), Malaysian Endocrine & Metabolic Society (MEMS), 2004.

124. Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000;23:13-19.

125. Martínez-Momblán MA, Santos A, Resmini E, et al. Guía educativa para pacientes con síndrome de Cushing. Disponible en: https://www.orpha.net/data/patho/ Pub/es/GuiaSindromeCushing.pdf; consultado: mayo 23, 2014.

126. Morales-González JA. Obesidad, un enfoque multidisciplinario. Universidad Autónoma del Estado de Hidalgo (UAEH). Pachuca, Hidalgo, 2010.

127. Sociedad Española de Endocrinología y Nutrición (SEEN). Síndrome de Cushing. Disponible en: http://www.seen.es/ docs/publico/enfermedades/glandula-adrenal/sindromede- cushing.pdf; consultado: mayo 23, 2014.

128. Sabán-Ruiz J, Cuesta-Muñoz AL. La obesidad como entidad pluripatológica. Madrid: Ediciones Díaz de Santos, 2012.